The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 05, 2020
Filed:
Feb. 04, 2019
Applicant:
Isofol Medical Ab, Göteborg, SE;
Inventors:
Göran U. Carlsson, Jonsered, SE;
Bengt Gustavsson, Västra Froelunda, SE;
Elisabeth Odin, Gothenburg, SE;
Yvonne Wettergren, Göteborg, SE;
Anders Vedin, Göteborg, SE;
Assignee:
Isofol Medical AB, Göteborg, SE;
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 31/555 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); C07K 16/22 (2006.01); A61K 9/00 (2006.01); A61K 31/282 (2006.01); A61K 31/4545 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 9/0019 (2013.01); A61K 31/282 (2013.01); A61K 31/4545 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/555 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01);
Abstract
The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.